Page last updated: 2024-09-03

ym 529 and Carcinoma, Small Cell

ym 529 has been researched along with Carcinoma, Small Cell in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Goto, H; Kanematsu, T; Miki, T; Muguruma, H; Sone, S; Uehara, H; Yano, S; Zhang, H	1
Goto, H; Hanibuchi, M; Miki, T; Sone, S; Uehara, H; Yano, S; Zhang, H	1

Other Studies

2 other study(ies) available for ym 529 and Carcinoma, Small Cell

Article	Year
A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice. Clinical & experimental metastasis, 2003, Volume: 20, Issue:2 Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Carcinoma, Small Cell; Cell Division; Cytokines; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Growth Factors; Humans; Imidazoles; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Lymphocyte Depletion; Lymphokines; Male; Mice; Mice, SCID; Osteolysis; Parathyroid Hormone-Related Protein; Peptide Hormones; Severe Combined Immunodeficiency; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2003
Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Nov-01, Volume: 9, Issue:14 Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Carcinoma, Small Cell; Cell Division; Diphosphonates; Drug Combinations; Etoposide; Humans; Imidazoles; Kidney Neoplasms; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Mice; Mice, Inbred ICR; Mice, SCID; Osteoclasts; Parathyroid Hormone-Related Protein; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A	2003

Article

Year

A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice.

Clinical & experimental metastasis, 2003, Volume: 20, Issue:2

Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Carcinoma, Small Cell; Cell Division; Cytokines; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Growth Factors; Humans; Imidazoles; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Lymphocyte Depletion; Lymphokines; Male; Mice; Mice, SCID; Osteolysis; Parathyroid Hormone-Related Protein; Peptide Hormones; Severe Combined Immunodeficiency; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2003

Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Nov-01, Volume: 9, Issue:14

Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Carcinoma, Small Cell; Cell Division; Diphosphonates; Drug Combinations; Etoposide; Humans; Imidazoles; Kidney Neoplasms; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Mice; Mice, Inbred ICR; Mice, SCID; Osteoclasts; Parathyroid Hormone-Related Protein; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A

2003